journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/30220624/another-step-towards-improving-oncofertility-counselling-of-young-women-with-hodgkin-s-lymphoma
#1
Matteo Lambertini, Isabelle Demeestere
No abstract text is available yet for this article.
September 13, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30220623/shortfall-of-consultant-clinical-radiologists-in-the-uk
#2
Talha Khan Burki
No abstract text is available yet for this article.
September 13, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30220622/determinants-of-ovarian-function-after-response-adapted-therapy-in-patients-with-advanced-hodgkin-s-lymphoma-rathl-a-secondary-analysis-of-a-randomised-phase-3-trial
#3
Richard A Anderson, Rachel Remedios, Amy A Kirkwood, Pip Patrick, Linsey Stevens, Laura Clifton-Hadley, Tom Roberts, Chris Hatton, Nagesh Kalakonda, Don W Milligan, Pam McKay, Clare Rowntree, Fiona M Scott, Peter W M Johnson
BACKGROUND: Adverse effects on reproductive function are a key concern in young women treated with chemotherapy for advanced Hodgkin's lymphoma. We aimed to identify risk factors for the extent of ovarian damage in women with Hodgkin's lymphoma treated with different chemotherapy regimens to inform accurate advice on options for fertility preservation. METHODS: We recruited female participants from the randomised phase 3 RATHL trial, aged 18-45 years, based on availability of participants at recruiting sites in the UK...
September 13, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30219628/overall-survival-in-patients-with-braf-mutant-melanoma-receiving-encorafenib-plus-binimetinib-versus-vemurafenib-or-encorafenib-columbus-a-multicentre-open-label-randomised-phase-3-trial
#4
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Jan Willem B de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D Pickard, Victor Sandor, Caroline Robert, Keith T Flaherty
BACKGROUND: Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600 -mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. METHODS: COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAFV600E or BRAFV600K mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had progressed on or after first-line immunotherapy...
September 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30219625/encorafenib-plus-binimetinib-an-embarrassment-of-riches
#5
Juan Martin-Liberal
No abstract text is available yet for this article.
September 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30219627/cancer-trends-and-disparities-in-india-data-needs-for-providing-equitable-cancer-care
#6
Surendra S Shastri
No abstract text is available yet for this article.
September 11, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30219626/the-burden-of-cancers-and-their-variations-across-the-states-of-india-the-global-burden-of-disease-study-1990-2016
#7
(no author information available yet)
BACKGROUND: Previous efforts to report estimates of cancer incidence and mortality in India and its different parts include the National Cancer Registry Programme Reports, Sample Registration System cause of death findings, Cancer Incidence in Five Continents Series, and GLOBOCAN. We present a comprehensive picture of the patterns and time trends of the burden of total cancer and specific cancer types in each state of India estimated as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 because such a systematic compilation is not readily available...
September 11, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30217674/tomas-revisiting-parp-inhibitor-combination-therapy
#8
Benjamin A Nacev, William D Tap
No abstract text is available yet for this article.
September 11, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30217673/pertuzumab-therapy-for-her2-positive-metastatic-gastric-or-gastro-oesophageal-junction-cancer
#9
Giandomenico Roviello, Daniele Generali
No abstract text is available yet for this article.
September 11, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30217672/pertuzumab-plus-trastuzumab-and-chemotherapy-for-her2-positive-metastatic-gastric-or-gastro-oesophageal-junction-cancer-jacob-final-analysis-of-a-double-blind-randomised-placebo-controlled-phase-3-study
#10
Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim, Yoon-Koo Kang
BACKGROUND: Adding pertuzumab to trastuzumab and chemotherapy improves survival in HER2-positive early breast cancer and metastatic breast cancer. We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer. METHODS: JACOB was a double-blind, placebo-controlled, randomised, multicentre, phase 3 trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer...
September 11, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30217671/trabectedin-and-olaparib-in-patients-with-advanced-and-non-resectable-bone-and-soft-tissue-sarcomas-tomas-an-open-label-phase-1b-study-from-the-italian-sarcoma-group
#11
Giovanni Grignani, Lorenzo D'Ambrosio, Ymera Pignochino, Emanuela Palmerini, Massimo Zucchetti, Paola Boccone, Sandra Aliberti, Silvia Stacchiotti, Rossella Bertulli, Raimondo Piana, Sara Miano, Francesco Tolomeo, Giulia Chiabotto, Dario Sangiolo, Alberto Pisacane, Angelo Paolo Dei Tos, Luca Novara, Alice Bartolini, Emanuela Marchesi, Maurizio D'Incalci, Alberto Bardelli, Piero Picci, Stefano Ferrari, Massimo Aglietta
BACKGROUND: Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma...
September 11, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30213452/camrelizumab-shr-1210-alone-or-in-combination-with-gemcitabine-plus-cisplatin-for-nasopharyngeal-carcinoma-results-from-two-single-arm-phase-1-trials
#12
Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, Shaodong Hong, Lizhu Lin, Xiaohui He, Jianping Xiong, Ping Li, Hongyun Zhao, Yan Huang, Yang Zhang, Likun Chen, Ningning Zhou, Yuanyuan Zhao, Xue Hou, Qing Yang, Li Zhang
BACKGROUND: Platinum-based doublet chemotherapy regimens, preferentially gemcitabine plus cisplatin, are generally considered the first-line standard of care for patients with recurrent or metastatic nasopharyngeal carcinoma. However, no consensus has been reached regarding treatment following progression after first-line therapy. Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody. We present safety and preliminary antitumour activity of camrelizumab alone as second-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma and combined with gemcitabine and cisplatin as first-line therapy in this patient population...
September 10, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30213451/camrelizumab-for-nasopharyngeal-carcinoma-a-new-hope
#13
Dora L W Kwong
No abstract text is available yet for this article.
September 10, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30213450/quality-of-life-is-not-compromised-with-intensification-of-androgen-therapy-in-recurrent-prostate-cancer
#14
Zachary Seymour, Daniel Hamstra
No abstract text is available yet for this article.
September 10, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30213449/effect-of-apalutamide-on-health-related-quality-of-life-in-patients-with-non-metastatic-castration-resistant-prostate-cancer-an-analysis-of-the-spartan-randomised-placebo-controlled-phase-3-trial
#15
Fred Saad, David Cella, Ethan Basch, Boris A Hadaschik, Paul N Mainwaring, Stéphane Oudard, Julie N Graff, Kelly McQuarrie, Susan Li, Stacie Hudgens, Joe Lawson, Angela Lopez-Gitlitz, Margaret K Yu, Matthew R Smith, Eric J Small
BACKGROUND: In the SPARTAN trial, addition of apalutamide to androgen deprivation therapy, as compared with placebo plus androgen deprivation therapy, significantly improved metastasis-free survival in men with non-metastatic castration-resistant prostate cancer who were at high risk for development of metastases. We aimed to investigate the effects of apalutamide versus placebo added to androgen deprivation therapy on health-related quality of life (HRQOL). METHODS: SPARTAN is a multicentre, international, randomised, phase 3 trial...
September 10, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30197174/maternal-use-of-hormonal-contraception-and-risk-of-childhood-leukaemia-a-nationwide-population-based-cohort-study
#16
Marie Hargreave, Lina S Mørch, Klaus K Andersen, Jeanette F Winther, Kjeld Schmiegelow, Susanne K Kjaer
BACKGROUND: Maternal hormonal contraception has been suspected of being linked to an increased risk of childhood cancer. The aim of this study was to assess the association between maternal use of hormonal contraception and diagnosis of leukaemia in their children. METHODS: In this cohort study, we followed a nationwide cohort of 1 185 157 liveborn children between 1996 and 2014 listed in the Danish Medical Birth Registry and identified those diagnosed with leukaemia in the Danish Cancer Registry...
September 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30197173/preliminary-activity-of-capmatinib-with-gefitinib-in-nsclc
#17
Talha Khan Burki
No abstract text is available yet for this article.
September 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30197172/cns-efficacy-of-osimertinib-in-egfr-mutated-advanced-nsclc
#18
Elizabeth Gourd
No abstract text is available yet for this article.
September 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30197171/maternal-hormonal-contraception-and-childhood-leukaemia
#19
Maria S Pombo-de-Oliveira
No abstract text is available yet for this article.
September 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30196032/more-evidence-for-further-minimisation-of-breast-cancer-surgery
#20
Henry M Kuerer
No abstract text is available yet for this article.
September 5, 2018: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"